Missing links in multiple sclerosis etiology. A working connecting hypothesis

Medical Hypotheses

Volumn 80, Issue 5, 2013, Pages 509-516

  Soulillou, Jean Paul ^a,b,c  

^a Centre National de la Recherche Scientifique   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HETEROPHILE ANTIBODY; N GLYCOLOYLNEURAMINIC ACID;

ARTICLE; BLOOD BRAIN BARRIER; CLINICAL FEATURE; DEMOGRAPHY; ENDOTHELIUM CELL; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HEALTH STATUS; HUMAN; HYPOTHESIS; MEDICAL LITERATURE; MEMBRANE PERMEABILITY; MEMORY CELL; MULTIPLE SCLEROSIS; T LYMPHOCYTE;

ANIMALS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CYTOKINES; EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; MODELS, IMMUNOLOGICAL; MULTIPLE SCLEROSIS; T-LYMPHOCYTES;

HUMAN HERPESVIRUS 4;

EID: 84875600014     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.01.036     Document Type: Article

References (90)

1. Ioannidis J.P. Why most published research findings are false. PLoS Med 2005, 2:e124.
2. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517.
3. Lassmann H., Bruck W., Lucchinetti C.F. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007, 17:210-218.
4. Rudick R.A., Stuart W.H., Calabresi P.A., et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006, 354:911-923.
5. Hauser S.L., Waubant E., Arnold D.L., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358:676-688.
6. Devonshire V., Havrdova E., Radue E.W., et al. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol 2012, 11:420-428.
7. Meier U.C., Giovannoni G., Tzartos J.S., Khan G. Translational mini-review series on B cell subsets in disease. B cells in multiple sclerosis: drivers of disease pathogenesis and Trojan horse for Epstein-Barr virus entry to the central nervous system?. Clin Exp Immunol 2012, 167:1-6.
8. Stys P.K., Zamponi G.W., van Minnen J., Geurts J.J. Will the real multiple sclerosis please stand up?. Nat Rev Neurosci 2012, 13:507-514.
9. t Hart B.A., Hintzen R.Q., Laman J.D. Multiple sclerosis - a response-to-damage model. Trends Mol Med 2009, 15:235-244.
10. Engelhardt B. Molecular mechanisms involved in T cell migration across the blood-brain barrier. J Neural Transm 2006, 113:477-485.
11. Liu X., Leung S., Wang C., et al. Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease. Nat Med 2010, 16:191-197.
12. t Hart B.A., Gran B., Weissert R. EAE: imperfect but useful models of multiple sclerosis. Trends Mol Med 2011, 17:119-125.
13. Wekerle H., Flugel A., Fugger L., Schett G., Serreze D. Autoimmunity's next top models. Nat Med 2012, 18:66-70.
14. Oksenberg J.R., Baranzini S.E. Multiple sclerosis genetics-is the glass half full, or half empty?. Nat Rev Neurol 2010, 6:429-437.
15. Sawcer S., Hellenthal G., Pirinen M., et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219.
16. Baranzini S.E., Nickles D. Genetics of multiple sclerosis: swimming in an ocean of data. Curr Opin Neurol 2012, 25:239-245.
17. Hafler D.A., Compston A., Sawcer S., et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007, 357:851-862.
18. Palace J. Multiple sclerosis associated with Leber's hereditary optic neuropathy. J Neurol Sci 2009, 286:24-27.
19. Stockler S., Millner M., Molzer B., Ebner F., Korner E., Moser H.W. Multiple sclerosis-like syndrome in a woman heterozygous for adrenoleukodystrophy. Eur Neurol 1993, 33:390-392.
20. Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G. Multiple sclerosis. N Engl J Med 2000, 343:938-952.
21. Rook G.A. Hygiene hypothesis and autoimmune diseases. Clin Rev Allergy Immunol 2012, 42:5-15.
22. Kawakami N., Lassmann S., Li Z., et al. The activation status of neuroantigen-specific T cells in the target organ determines the clinical outcome of autoimmune encephalomyelitis. J Exp Med 2004, 199:185-197.
23. Bartholomaus I., Kawakami N., Odoardi F., et al. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature 2009, 462:94-98.
24. Bettelli E., Baeten D., Jager A., Sobel R.A., Kuchroo V.K. Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J Clin Invest 2006, 116:2393-2402.
25. Munder M., Bettelli E., Monney L., Slavik J.M., Nicholson L.B., Kuchroo V.K. Reduced self-reactivity of an autoreactive T cell after activation with cross-reactive non-self-ligand. J Exp Med 2002, 196:1151-1162.
26. Elong Ngono A., Pettre S., Salou M., et al. Frequency of circulating autoreactive T cells committed to myelin determinants in relapsing-remitting multiple sclerosis patients. Clin Immunol 2012, 144:117-126.
27. Owens G.P., Gilden D., Burgoon M.P., Yu X., Bennett J.L. Viruses and multiple sclerosis. Neuroscientist 2011, 17:659-676.
28. Padler-Karavani V., Yu H., Cao H., et al. Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease. Glycobiology 2008, 18:818-830.
29. Pham T., Gregg C.J., Karp F., et al. Evidence for a novel human-specific xeno-auto-antibody response against vascular endothelium. Blood 2009, 114:5225-5235.
30. Diaz S.L., Padler-Karavani V., Ghaderi D., et al. Sensitive and specific detection of the non-human sialic Acid N-glycolylneuraminic acid in human tissues and biotherapeutic products. PLoS One 2009, 4:e4241.
31. Shaw L., Schauer R. The biosynthesis of N-glycoloylneuraminic acid occurs by hydroxylation of the CMP-glycoside of N-acetylneuraminic acid. Biol Chem Hoppe Seyler 1988, 369:477-486.
32. Tangvoranuntakul P., Gagneux P., Diaz S., et al. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci USA 2003, 100:12045-12050.
33. Burgio G.R., Monafo V. Infectious mononucleosis fifty years after the discovery of the Paul-Bunnell test. Infection 1983, 11:1-5.
34. Pender M.P. The essential role of Epstein-Barr virus in the pathogenesis of multiple sclerosis. Neuroscientist 2011, 17:351-367.
35. Callan M.F., Tan L., Annels N., et al. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med 1998, 187:1395-1402.
36. Hochberg D., Souza T., Catalina M., Sullivan J.L., Luzuriaga K., Thorley-Lawson D.A. Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells. J Virol 2004, 78:5194-5204.
37. Wilson D.B., Wilson D.H., Schroder K., et al. Specificity and degeneracy of T cells. Mol Immunol 2004, 40:1047-1055.
38. Lang H.L., Jacobsen H., Ikemizu S., et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 2002, 3:940-943.
39. Benoist C., Mathis D. Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry?. Nat Immunol 2001, 2:797-801.
40. Wekerle H., Hohlfeld R. Molecular mimicry in multiple sclerosis. N Engl J Med 2003, 349:185-186.
41. van Sechel A.C., Bajramovic J.J., van Stipdonk M.J., Persoon-Deen C., Geutskens S.B., van Noort J.M. EBV-induced expression and HLA-DR-restricted presentation by human B cells of alpha B-crystallin, a candidate autoantigen in multiple sclerosis. J Immunol 1999, 162:129-135.
42. Lucas R.M., Hughes A.M., Lay M.L., et al. Epstein-Barr virus and multiple sclerosis. J Neurol Neurosurg Psychiatry 2011, 82:1142-1148.
43. Compston A. Risk factors for multiple sclerosis: race or place?. J Neurol Neurosurg Psychiatry 1990, 53:821-823.
44. Confavreux C., Hutchinson M., Hours M.M., Cortinovis-Tourniaire P., Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998, 339:285-291.
45. Bahbouhi B., Berthelot L., Pettre S., et al. Peripheral blood CD4+ T lymphocytes from multiple sclerosis patients are characterized by higher PSGL-1 expression and transmigration capacity across a human blood-brain barrier-derived endothelial cell line. J Leukoc Biol 2009, 86:1049-1063.
46. Marino E., Grey S.T. B cells as effectors and regulators of autoimmunity. Autoimmunity 2012, 45:377-387.
47. Karni A., Abraham M., Monsonego A., et al. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J Immunol 2006, 177:4196-4202.
48. Balashov K.E., Smith D.R., Khoury S.J., Hafler D.A., Weiner H.L. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci USA 1997, 94:599-603.
49. Bahbouhi B., Pettre S., Berthelot L., et al. T cell recognition of self-antigen presenting cells by protein transfer assay reveals a high frequency of anti-myelin T cells in multiple sclerosis. Brain 2010, 133:1622-1636.
50. Berthelot L., Laplaud D.A., Pettre S., et al. Blood CD8+ T cell responses against myelin determinants in multiple sclerosis and healthy individuals. Eur J Immunol 2008, 38:1889-1899.
51. Kim S.K., Cornberg M., Wang X.Z., Chen H.D., Selin L.K., Welsh R.M. Private specificities of CD8 T cell responses control patterns of heterologous immunity. J Exp Med 2005, 201:523-533.
52. Clute S.C., Watkin L.B., Cornberg M., et al. Cross-reactive influenza virus-specific CD8+ T cells contribute to lymphoproliferation in Epstein-Barr virus-associated infectious mononucleosis. J Clin Invest 2005, 115:3602-3612.
53. Golaszewska E., Kurowska E., Duk M., Koscielak J. Paul-Bunnell antigen and a possible mechanism of formation of heterophile antibodies in patients with infectious mononucleosis. Acta Biochim Pol 2003, 50:1205-1211.
54. Morito T., Kano K., Milgrom F. Hanganutziu-Deicher antibodies in infectious mononucleosis and other diseases. J Immunol 1982, 129:2524-2528.
55. Battistini L., Piccio L., Rossi B., et al. CD8+ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: a critical role for P-selectin glycoprotein ligand-1. Blood 2003, 101:4775-4782.
56. Baldini L.G., Cro L.M. Structure and function of VLA integrins: differential expression in B-cell leukemia/lymphoma. Leuk Lymphoma 1994, 12:197-203.
57. Planas R., Jelcic I., Schippling S., Martin R., Sospedra M. Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. Eur J Immunol 2012, 42:790-798.
58. Cepok S., Zhou D., Srivastava R., et al. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest 2005, 115:1352-1360.
59. Leech S., Kirk J., Plumb J., McQuaid S. Persistent endothelial abnormalities and blood-brain barrier leak in primary and secondary progressive multiple sclerosis. Neuropathol Appl Neurobiol 2007, 33:86-98.
60. Compston D.A., Morgan B.P., Campbell A.K., et al. Immunocytochemical localization of the terminal complement complex in multiple sclerosis. Neuropathol Appl Neurobiol 1989, 15:307-316.
61. Barnett M.H., Parratt J.D., Cho E.S., Prineas J.W. Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann Neurol 2009, 65:32-46.
62. Storch M.K., Piddlesden S., Haltia M., Iivanainen M., Morgan P., Lassmann H. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Ann Neurol 1998, 43:465-471.
63. Feucht H.E. Complement C4d in graft capillaries - the missing link in the recognition of humoral alloreactivity. Am J Transplant 2003, 3:646-652.
64. Barnett M.H., Prineas J.W. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004, 55:458-468.
65. Larochelle C., Alvarez J.I., Prat A. How do immune cells overcome the blood-brain barrier in multiple sclerosis?. FEBS Lett 2011, 585:3770-3780.
66. Dressel A., Mirowska-Guzel D., Gerlach C., Weber F. Migration of T-cell subsets in multiple sclerosis and the effect of interferon-beta1a. Acta Neurol Scand 2007, 116:164-168.
67. Koch M., den Dunnen W., Sie O.G., De Keyser J. A fatal demyelinating illness in a young woman 10 weeks post partum. Lancet Neurol 2005, 4:129-134.
68. Levin L.I., Munger K.L., Rubertone M.V., et al. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 2005, 293:2496-2500.
69. Ludwin S., Jacobson S. Epstein-Barr Virus and MS:Causality or Association?. Int MS J 2011, 17:39-43.
70. Selin L.K., Wlodarczyk M.F., Kraft A.R., et al. Heterologous immunity: immunopathology, autoimmunity and protection during viral infections. Autoimmunity 2011, 44:328-347.
71. Vink C., Beisser P.S., Bruggeman C.A. Molecular mimicry by cytomegaloviruses. Function of cytomegalovirus-encoded homologues of G protein-coupled receptors, MHC class I heavy chains and chemokines. Intervirology 1999, 42:342-349.
72. Frankild S., de Boer R.J., Lund O., Nielsen M., Kesmir C. Amino acid similarity accounts for T cell cross-reactivity and for " holes" in the T cell repertoire. PLoS One 2008, 3:e1831.
73. Casiraghi C., Dorovini-Zis K., Horwitz M.S. Epstein-Barr virus infection of human brain microvessel endothelial cells: a novel role in multiple sclerosis. J Neuroimmunol 2011, 230:173-177.
74. Ascherio A., Munger K.L., Lennette E.T., et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 2001, 286:3083-3088.
75. Martyn C.N., Cruddas M., Compston D.A. Symptomatic Epstein-Barr virus infection and multiple sclerosis. J Neurol Neurosurg Psychiatry 1993, 56:167-168.
76. Munger K.L., Levin L.I., O'Reilly E.J., Falk K.I., Ascherio A. Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Mult Scler 2011, 17:1185-1193.
77. Munch M., Riisom K., Christensen T., Moller-Larsen A., Haahr S. The significance of Epstein-Barr virus seropositivity in multiple sclerosis patients?. Acta Neurol Scand 1998, 97:171-174.
78. Wagner H.J., Hornef M., Teichert H.M., Kirchner H. Sex difference in the serostatus of adults to the Epstein-Barr virus. Immunobiology 1994, 190:424-429.
79. Nielsen T.R., Pedersen M., Rostgaard K., Frisch M., Hjalgrim H. Correlations between Epstein-Barr virus antibody levels and risk factors for multiple sclerosis in healthy individuals. Mult Scler 2007, 13:420-423.
80. Patarca R., Fletcher M.A. Structure and pathophysiology of the erythrocyte membrane-associated Paul-Bunnell heterophile antibody determinant in Epstein-Barr virus-associated disease. Crit Rev Oncog 1995, 6:305-326.
81. Lair D., Coupel S., Giral M., et al. The effect of a first kidney transplant on a subsequent transplant outcome: an experimental and clinical study. Kidney Int 2005, 67:2368-2375.
82. Weinshenker B.G., O'Brien P.C., Petterson T.M., et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999, 46:878-886.
83. Gwathmey K., Balogun R.A., Burns T. Neurologic indications for therapeutic plasma exchange: an update. J Clin Apher 2011, 26:261-268.
84. Kurtzke J.F., Delasnerie-Laupretre N. Reflection on the geographic distribution of multiple sclerosis in France. Acta Neurol Scand 1996, 93:110-117.
85. Kurtzke J.F. A reassessment of the distribution of multiple sclerosis. Part one. Acta Neurol Scand 1975, 51:110-136.
86. Silins S.L., Sherritt M.A., Silleri J.M., et al. Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load. Blood 2001, 98:3739-3744.
87. Fleming J.O., Cook T.D. Multiple sclerosis and the hygiene hypothesis. Neurology 2006, 67:2085-2086.
88. Fleming J.O., Isaak A., Lee J.E., et al. Probiotic helminth administration in relapsing-remitting multiple sclerosis: a phase 1 study. Mult Scler 2011, 17:743-754.
89. Hedlund M., Padler-Karavani V., Varki N.M., Varki A. Evidence for a human-specific mechanism for diet and antibody-mediated inflammation in carcinoma progression. Proc Natl Acad Sci USA 2008, 105:18936-18941.
90. Lauer K. The risk of multiple sclerosis in the USA in relation to sociogeographic features: a factor-analytic study. J Clin Epidemiol 1994, 47:43-48.